Skip to content
NP

Novelix Pharmaceuticals

536565 BSE
Price unavailable

Novelix Pharmaceuticals (NOVELIX) share price was ₹61.41 at the 28 Oct 2026 close; market capitalisation ₹175 Cr; P/E (TTM) 32.84; sector Retail. The share price rose 17.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 65.2% year on year to ₹36.91 Cr and net profit was ₹1.18 Cr, against ₹0.11 Cr a year earlier (compared with Jun 2025). Promoters held 54.29% of Novelix Pharmaceuticals in Sep 2026, up 3.72 percentage points from Jun 2026. Its Tapetide Score is 44/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹61.41 +6.50 +11.84% 1Y

Key Fundamentals

MicrocapRetailConsumer Services
Market Cap
₹175 Cr
P/E (TTM)
32.84
EBITDA
−₹2.00 Cr
Return on Equity
-26.4%
Return on Capital Employed
-26.06%
Debt to Equity
0
Book Value
₹23.08
EPS (TTM)
₹1.87
52W High
₹92.00
52W Low
₹49.01

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Retail › Pharmacy Retail › Healthcare Research, Analytics & Technology

Syngene International
₹406.2574.0016,399 Cr3.380.34%6.54%8.35%3,613 Cr221 Cr
Indegene
₹594.3035.6714,321 Cr4.560.38%12.78%15.40%3,892 Cr401 Cr
Suven Life Sciences
₹265.35—7,498 Cr10.950.00%-46.73%-45.62%30 Cr-353 Cr
Vimta Labs
₹514.6528.832,300 Cr5.040.39%12.83%16.36%336 Cr80 Cr
Fabtech Technologies
₹121.259.11539 Cr1.280.47%9.14%11.73%441 Cr49 Cr
Novelix Pharmaceuticals (this company)
—32.84175 Cr2.660.00%-26.40%-26.06%5 Cr4 Cr
Take
₹10.7712.38159 Cr5.130.00%13.73%15.37%100 Cr13 Cr
Median 7 companies₹335.8030.842,300 Cr4.560.34%9.14%11.73%336 Cr49 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

44 Weak
Overall score

Data confidence 95/100

Category scores

Quality Poor 12
Returns, margins, earnings quality 22% weight
Valuation Poor 27
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Good 64
Solvency, leverage, coverage 9% weight
Momentum Good 59
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

5
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Promoter holding has increased by 4.86% over last quarter.
  • Company's median sales growth is 42.1% of last 10 years
  • Company's working capital requirements have reduced from 218 days to 110 days

Weaknesses

5
  • Stock is trading at 3.08 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 5.12% over last 3 years.
  • Company has high debtors of 163 days.
  • Promoter holding has decreased over last 3 years: -12.6%

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bearish

Bearish
12
Neutral
6
Bullish
1

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-4.17% lower than 3Y

change over 1 year

Net Income Growth
-47.37% lower than 3Y

change over 1 year

Cash Flow Change
0%

change over 1 year

EBITDA Margin Change
317%

change over 1 year Operating margin 3.55% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1.95
0.93
0.5
0.84
0.6
3.96
5.3
20.86
22.35
36.36
48.4
25.19
36.91
Expenses
2.14
1.04
0.61
0.69
1.04
3.74
5.17
20.63
22.17
35.66
47.09
23.91
35.6
Operating Profit
-0.19
-0.11
-0.11
0.15
-0.44
0.22
0.13
0.23
0.18
0.7
1.31
1.28
1.31
OPM %
-9.74%
-11.83%
-22%
17.86%
-73.33%
5.56%
2.45%
1.1%
0.81%
1.93%
2.71%
5.08%
3.55%
Other Income
0.05
0.05
0.09
0.13
0.1
-0.08
0
0
0
0.03
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0.12
Depreciation
0.01
0.01
0.01
0.01
0
0
0
0.02
0.01
0.01
0.03
0.05
0.07
PBT
-0.15
-0.07
-0.03
0.27
-0.34
0.14
0.13
0.21
0.17
0.72
1.28
1.23
1.12
Tax %
6.67%
0%
0%
0%
2.94%
0%
-15.38%
14.29%
41.18%
26.39%
21.88%
26.02%
-5.36%
Net Profit
-0.17
-0.07
-0.03
0.28
-0.35
0.13
0.15
0.18
0.11
0.53
1
0.91
1.18
EPS (₹)
-0.21
-0.09
-0.04
0.35
-0.35
0.13
0.15
0.18
0.09
0.37
0.58
0.43
0.49
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1
1
4
3
4
2
1
1
2
4
31
132
147
Expenses
1
1
3
3
3
1
4
3
2
4
31
129
142
Operating Profit
0
0
0
0
0
0
-3
-2
0
0
0
4
5
OPM %
33%
43%
5%
15%
6%
12%
-244%
-151%
0%
-6%
0.5%
2.7%
3.1%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
-3
-2
0
0
0
3
4
Tax %
88%
31%
24%
34%
-32%
20%
0%
-1%
0%
50%
33%
25%
—
Net Profit
0
0
0
0
0
0
-3
-2
0
0
0
3
4
EPS (₹)
0.02
0.12
0.19
0.22
0.31
0.11
-4.04
-1.93
-0.07
0.01
0.08
1.21
1.87
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
8
8
8
8
8
8
8
10
21
Reserves
3
3
3
4
4
4
1
-1
-1
-1
8
25
Borrowings
0
0
0
0
0
0
0
0
0
0
0
0
Other Liabilities
0
0
0
0
0
0
0
0
0
0
10
46
Total Liabilities
12
12
12
12
12
12
9
7
7
7
27
92
Fixed Assets
1
1
1
1
0
0
0
2
0
0
0
3
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
1
3
2
3
3
4
4
1
3
3
0
0
Other Assets
9
8
9
9
9
8
5
5
4
4
27
89
Total Assets
12
12
12
12
12
12
9
7
7
7
27
92
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
2
-1
1
0
1
1
1
-2
0
-14
-22
Investing
0
-2
1
-1
0
0
0
0
0
0
3
-2
Financing
0
0
0
0
0
0
0
0
0
0
11
26
Net Cash Flow
-1
0
0
0
0
1
1
1
-2
0
1
2
Free Cash Flow
-1
2
-1
1
0
1
0
-1
-2
0
-14
-26
CFO/OP
-90
472
-535
225
-220
672
-18
-34
—
136
-9,771
-631
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
30
4
40
130
216
19
25
32
36
1
216
163
Inventory Days
0
—
28
19
13
39
89
239
222
113
10
42
Days Payable
—
—
0
54
13
5
4
0
14
0
114
116
Cash Conversion Cycle
30
4
68
95
216
54
111
271
244
114
112
88
Working Capital Days
2,225
2,584
863
932
858
1,711
819
647
743
346
197
110
ROCE %
1%
1%
1%
3%
1%
1%
-31%
-19%
-1%
0%
1%
11%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Novelix Pharmaceuticals insights

61 extracted metrics + investor summaries across FY09–FY27.

Shareholding Pattern

Promot.54.29%Others2.93%Public42.78%As ofSep 2026

Documents

Frequently Asked Questions about Novelix Pharmaceuticals

What does Novelix Pharmaceuticals Ltd do?
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]
Where is Novelix Pharmaceuticals Ltd (NOVELIX) listed?
Novelix Pharmaceuticals Ltd trades under code 536565 on the BSE.
Which sector does Novelix Pharmaceuticals Ltd belong to?
Novelix Pharmaceuticals Ltd is classified under the Retail sector, in the Pharmacy Retail industry.
What is the market capitalisation of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd has a market capitalisation of ₹174.81 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd trades at a PE ratio of 32.84 as of 28 Oct 2026, on earnings per share of ₹1.87, against a book value of ₹23.08 per share.
What is the 52-week high and low of Novelix Pharmaceuticals Ltd?
Over the last 52 weeks Novelix Pharmaceuticals Ltd has traded between ₹49.01 and ₹92 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Novelix Pharmaceuticals Ltd?
Novelix Pharmaceuticals Ltd reported a return on equity of -26.40%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]

Website trimurthidrugs.com
Face Value ₹ 10
Shares Outstanding 2,84,66,688

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/536565.md for Novelix Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month